Sangamo - Zinc Finger (ZF) Technologies
Sangamo’s proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity and clinical utility. Zinc finger technologies are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic need. Due to their compact size, ZF technologies are highly vector compatible. Partnering ZF technologies with delivery vectors allows for the creation of ZF-based genomic medicines.
Sangamo’s zinc finger platform can be used to create genomic medicines for ex vivo for cell therapy and in vivo for genome engineering:
An example of ex vivo cell therapy application includes CAR-Tregs produced by Sangamo using ZF engineering to address immune-mediated diseases.
An example of in vivo genome engineering application includes the use of zinc fingers coupled to transcription factor domains to create genomic medicines that can regulate gene expression in neurological diseases.
